Healthcare / Drug Manufacturers - Specialty & GenericToronto
$0.07
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-5.6M · quality 61.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$32M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-23.1%
↓Gross Margin
31.0%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+26.8%
FCF CAGR
—
FCF margin
-12.4%
FCF / Net income
0.68x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $45.1M · net income $-8.3M · FCF $-5.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $45.1M | $45.1M | $42.0M | $33.1M | $22.1M |
| Net Income | $-8.3M | $-8.3M | $-10.7M | $-13.1M | $-30.0M |
| EBITDA | $-6.5M | $-6.5M | $-7.5M | $-10.5M | $-27.1M |
| EPS | -0.02 | -0.02 | -0.03 | -0.04 | -0.11 |
| Gross Margin | 31.0% | 31.0% | 30.5% | 17.7% | -8.7% |
| Operating Margin | -18.6% | -18.6% | -26.0% | -53.7% | -130.1% |
| Net Margin | -18.3% | -18.3% | -25.5% | -39.6% | -135.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.04 | 0.01 |
| Current Ratio | 3.02 | 3.02 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-5.6M | $-5.6M | $-5.0M | $-12.8M | $-16.9M |
| Returns | |||||
| ROE | -23.1% | -23.1% | -24.8% | -24.7% | -53.5% |
| Valuation | |||||
| P/B | 0.88 | 0.88 | 0.61 | 0.45 | 0.35 |
| Growth & Yield | |||||
| Revenue Growth | 7.5% | 7.5% | 26.9% | 49.5% | — |
| EPS Growth | 33.3% | 33.3% | 25.0% | 63.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+0.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.03 → -0.02
Residual
+0.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.